Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Lawrence Martuza, M.D.

Co-Author

This page shows the publications co-authored by Robert Martuza and Hiroaki Wakimoto.
Connection Strength

3.445
  1. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol Commun. 2020 12 11; 8(1):221.
    View in: PubMed
    Score: 0.234
  2. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902.
    View in: PubMed
    Score: 0.233
  3. A Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Target Oncol. 2019 08; 14(4):479-489.
    View in: PubMed
    Score: 0.213
  4. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019 Jun 28; 13:58-66.
    View in: PubMed
    Score: 0.208
  5. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
    View in: PubMed
    Score: 0.205
  6. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clin Cancer Res. 2018 07 15; 24(14):3409-3422.
    View in: PubMed
    Score: 0.194
  7. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.
    View in: PubMed
    Score: 0.186
  8. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87.
    View in: PubMed
    Score: 0.168
  9. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016; 6(2):300-11.
    View in: PubMed
    Score: 0.167
  10. Targeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul; 74(7):710-22.
    View in: PubMed
    Score: 0.160
  11. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 2015 Jan; 121(1):91-100.
    View in: PubMed
    Score: 0.152
  12. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013 Jun; 15(6):591-9.
    View in: PubMed
    Score: 0.139
  13. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012 Apr; 1(4):322-32.
    View in: PubMed
    Score: 0.128
  14. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012 Jan 04; 104(1):42-55.
    View in: PubMed
    Score: 0.125
  15. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44.
    View in: PubMed
    Score: 0.125
  16. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011 Dec 01; 17(23):7383-93.
    View in: PubMed
    Score: 0.124
  17. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010 May 15; 70(10):3890-5.
    View in: PubMed
    Score: 0.112
  18. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
    View in: PubMed
    Score: 0.104
  19. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019 07 02; 10(1):2910.
    View in: PubMed
    Score: 0.053
  20. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of ?34.5 in Glioblastoma Stem-Like Cells. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.050
  21. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. J Natl Cancer Inst. 2017 03 01; 109(3):1-13.
    View in: PubMed
    Score: 0.045
  22. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20; 344(6190):1396-401.
    View in: PubMed
    Score: 0.037
  23. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94.
    View in: PubMed
    Score: 0.037
  24. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11.
    View in: PubMed
    Score: 0.035
  25. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79.
    View in: PubMed
    Score: 0.035
  26. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748.
    View in: PubMed
    Score: 0.033
  27. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.
    View in: PubMed
    Score: 0.033
  28. Effect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol. 2012 Apr; 86(8):4420-31.
    View in: PubMed
    Score: 0.032
  29. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 01; 17(11):3686-96.
    View in: PubMed
    Score: 0.030
  30. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4822-7.
    View in: PubMed
    Score: 0.026
  31. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res. 2007 Oct 01; 13(19):5897-902.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.